Target Name: TCOF1
NCBI ID: G6949
Other Name(s): TCOF_HUMAN | TCOF1 variant 2 | Treacher collins syndrome protein | TCOF1 variant 5 | Treacle protein (isoform b) | treacle protein | TCOF1 variant 7 | Treacle protein (isoform e) | treacle | Treacle ribosome biogenesis factor 1, transcript variant 2 | Treacle ribosome biogenesis factor 1, transcript variant 4 | treacle ribosome biogenesis factor 1 | Treacher Collins syndrome protein | TCS1 | Treacle protein | Treacle ribosome biogenesis factor 1, transcript variant 1 | TCOF1 variant 1 | TCS | TCOF1 variant 4 | MFD1 | Treacle | Treacle protein (isoform d) | Treacle ribosome biogenesis factor 1, transcript variant 5 | Treacher Collins-Franceschetti syndrome 1 | Nucleolar trafficking phosphoprotein | Treacle ribosome biogenesis factor 1, transcript variant 7 | Treacle protein (isoform g) | Treacle protein (isoform a) | nucleolar trafficking phosphoprotein

TCOF1: A Promising Drug Target and Biomarker for the Treatment of Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50 million people are affected by chronic pain, with 200,000 people dying each year due to chronic pain-related conditions. Chronic pain can be caused by various conditions, including musculoskeletal disorders, neuropathies, and chronic diseases such as diabetes and cancer. The persistent nature of chronic pain can significantly impact an individual's quality of life, making it an important topic for researchers and healthcare professionals to address.

TCOF1: A Potential Drug Target and Biomarker

TCOF1 (Transient Constrictor Oncolytic Factor 1) is a protein that has been identified as a potential drug target and biomarker for the treatment of chronic pain. TCOF1 plays a crucial role in the regulation of smooth muscle contractions, which are essential for maintaining posture, movement, and other physiological functions. The abnormal regulation of smooth muscle contractions can contribute to the development and maintenance of chronic pain conditions.

In recent years, the discovery of TCOF1 as a potential drug target has generated significant interest in the development of compounds that can modulate TCOF1 activity. Several studies have shown that TCOF1 can be modulated by various drugs, including small molecules, peptides, and antibodies. These modifications in TCOF1 activity can potentially lead to the development of new treatments for chronic pain.

TCOF1 as a Biomarker

TCOF1 has also been identified as a potential biomarker for the assessment of chronic pain. The levels of TCOF1 in pain-related tissues, such as muscle and bone, can be affected by various factors, including pain intensity, pain duration, and the presence of other disease conditions. Therefore, measuring the levels of TCOF1 in pain-related tissues can provide valuable information about the severity and duration of pain, which can be used to guide the choice of treatment options.

In addition, TCOF1 has been shown to be involved in the modulation of pain sensitivity. Studies have shown that TCOF1 can modulate pain sensitivity in various ways, including increasing pain sensitivity to low intensity stimuli and decreasing pain sensitivity to high intensity stimuli. These findings suggest that TCOF1 may be a potential target for the development of pain-modulating drugs.

TCOF1 as a Potential Drug

The potential of TCOF1 as a drug target and biomarker for the treatment of chronic pain has led to the development of several investigational compounds. These compounds aim to modulate TCOF1 activity and may potentially lead to the development of new treatments for chronic pain.

One of the most promising compounds is a peptide called P3-100, which is derived from the N-terminal region of TCOF1. P3-100 has been shown to be a potent modulator of TCOF1 activity, with a 10-fold increase in TCOF1 activity in pain-related tissues. P3-100 has also been shown to be safe and has potential for use in the treatment of chronic pain conditions.

Another promising compound is a small molecule called U-8719, which is a potent inhibitor of TCOF1 activity. U-8719 has been shown to be effective in reducing pain in pain-related tissues and has the potential to be used in the treatment of chronic pain conditions.

Conclusion

TCOF1 is a protein that has been identified as a potential drug target and biomarker for the treatment of chronic pain. The discovery of TCOF1 as a potential drug target has generated significant interest in

Protein Name: Treacle Ribosome Biogenesis Factor 1

Functions: Nucleolar protein that acts as a regulator of RNA polymerase I by connecting RNA polymerase I with enzymes responsible for ribosomal processing and modification (PubMed:12777385, PubMed:26399832). Required for neural crest specification: following monoubiquitination by the BCR(KBTBD8) complex, associates with NOLC1 and acts as a platform to connect RNA polymerase I with enzymes responsible for ribosomal processing and modification, leading to remodel the translational program of differentiating cells in favor of neural crest specification (PubMed:26399832)

More Common Targets

TCP1 | TCP10L | TCP10L2 | TCP10L3 | TCP11 | TCP11L1 | TCP11L2 | TCP11X2 | TCTA | TCTE1 | TCTN1 | TCTN2 | TCTN3 | TDG | TDGF1 | TDGF1P3 | TDGP1 | TDH | TDH-AS1 | TDO2 | TDP1 | TDP2 | TDRD1 | TDRD10 | TDRD12 | TDRD15 | TDRD3 | TDRD5 | TDRD6 | TDRD7 | TDRD9 | TDRG1 | TDRKH | TDRKH-AS1 | TDRP | TEAD1 | TEAD2 | TEAD3 | TEAD4 | TEC | TECPR1 | TECPR2 | TECR | TECRL | TECTA | TECTB | TEDC1 | TEDC2 | TEDC2-AS1 | TEDDM1 | TEF | TEFM | TEK | TEKT1 | TEKT2 | TEKT3 | TEKT4 | TEKT4P1 | TEKT4P2 | TEKT5 | TEKTIP1 | TELO2 | Telomerase holoenzyme complex | TEN1 | TEN1-CDK3 | Teneurin | TENM1 | TENM2 | TENM2-AS1 | TENM3 | TENM3-AS1 | TENM4 | TENT2 | TENT4A | TENT4B | TENT5A | TENT5B | TENT5C | TENT5C-DT | TENT5D | TEP1 | TEPP | TEPSIN | TERB1 | TERB2 | TERC | TERF1 | TERF1P3 | TERF2 | TERF2IP | TERLR1 | TERT | TES | TESC | TESK1 | TESK2 | TESMIN | TESPA1 | TET1 | TET2